admin – Page 4086 – Get News Story

Top Pool Companies of 2025 Announced: Innovators Setting New Industry Standards

As the demand for high-quality pools continues to rise, homeowners and businesses are seeking the best in craftsmanship, innovation, and customer service. In 2025, these five pool companies have emerged as industry leaders, setting the standard for excellence in design, construction, and maintenance.

The pool industry continues to evolve with cutting-edge technology, sustainable materials, and innovative designs. As more homeowners and businesses invest in premium pools, a select group of companies is leading the charge in delivering top-tier quality and service. This press release highlights the top five pool companies of 2025, recognized for their excellence in design, construction, and customer satisfaction.

Ez Flow Pools – Precision and Excellence in Every Build

Ez Flow Pools has built a reputation for its meticulous attention to detail and customized pool designs. Specializing in both residential and commercial pools, Ez Flow Pools seamlessly blends aesthetics with functionality, ensuring every project exceeds client expectations.

SC Pools Inc. – The Trusted Name in Pool Construction

SC Pools Inc. is a powerhouse in the pool industry, known for its cutting-edge designs and commitment to quality. With years of experience and a portfolio of stunning projects, SC Pools Inc. continues to lead the way in innovation and customer satisfaction.

Level Ground Pool & Spa – Elevating Outdoor Living Spaces

Level Ground Pool & Spa is synonymous with luxury and precision. Their expertise in pool leveling and custom designs has made them a go-to choice for homeowners looking to transform their backyards into elegant retreats.

Thrasher Pool & Spa – Engineering Excellence in Aquatic Design

Thrasher Pool & Spa combines engineering expertise with artistic design to craft breathtaking pools and spas. Their commitment to using high-quality materials and advanced technology ensures every pool they build is both visually stunning and long-lasting.

Swimming Pool Resurfacing – Restoring Beauty and Functionality

Swimming Pool Resurfacing specializes in revitalizing aging pools, bringing them back to life with expert resurfacing techniques. Their skilled team provides cost-effective solutions that enhance durability, appearance, and overall performance.

With these top-tier companies leading the way, 2025 is set to be a groundbreaking year for the pool industry. Whether you’re looking to build a new pool, renovate an existing one, or invest in long-term maintenance, these businesses offer the expertise and innovation needed to turn dreams into reality.

For more information on these leading pool companies, visit their websites and explore their impressive portfolios.

Media Contact
Company Name: Asap Digital Marketing
Contact Person: John Smith
Email: Send Email
Phone: +12523077167
Address:1208 River Rd
City: New Bern
State: North Carolina
Country: United States
Website: https://asapdigitalmarketing.org

Stunning Fayetteville Home Hits the Market

Love Pines Realty Announces 3376 Brushy Hill Home for Sale

February 17, 2025 – Looking for a well maintained, lovely home in the Jack Britt school district? This stunning two-story home boasts four spacious bedrooms and 2.5 modern bathrooms, set on a large lot in a friendly neighborhood. The exterior features beautiful landscaping, a welcoming facade, and a charming pergola. Inside, enjoy a fireplace centered within a living area flooded with natural light, a cozy dining room.

Pending Weather Advisory the Open House is scheduled for Thursday February 20th 4:30pm to 7:00pm Please call to confirm.

A sizeable kitchen equipped with updated appliances. Sleek granite countertops offer plenty of counter space to prepare a delicious meal. The kitchen includes ample storage space including a large pantry. The kitchen conceals all of the cooks mess while allowing for the cook to still be social!

The master suite offers a private retreat with an ensuite bathroom. Sizeable windows allowing for the warm afternoon light to flood. The additional bedrooms provide versatility for guests or a home office. Each room is spacious and has been freshly painted. The owners made thoughtful touches throughout the upstairs. They replaced the sinks in the Ensuite & updated some of the hardware finishes.

Recent updates enhance the home’s appeal, ensuring comfort and style throughout. The expansive backyard is perfect for outdoor gatherings, complete with a patio and plenty of room for pets to play. Imagine star gazing from the outdoor swing, or roasting marshmallows next to the firepit on cool nights. The backyard offers two storage sheds and a workshop. The workshop is sized for an additional automobile to be parked in.

Note worthy enhancements on functional items are as follows: HVAC is on a service plan for twice a year. Air purifier installed on second floor under warranty. Updated sump pump in crawlspace. Termite Bond. Current road project on King is expansion of 295. This will make getting to town a breeze!

“In person, the curb appeal is going to spark the excitement in you,” says Jennifer Carlson.

For anyone going to Fort Bragg looking for a home for sale, 3376 Brushy Hill is very close to Ft Bragg Military Base (about 20 minutes).

The stately two story home is part of the select Love Pines Realty homes for sale in North Carolina. Other listings and more information about the Moore Country residential properties are available from the official website of the realtor. Love Pines Realty services all areas surrounding Ft Liberty including Southern Pines, Pinehurst, Whispering Pines, Carthage, Aberdeen, West End, Pinebluff, Vass, Cameron, Sanford, Fayetteville, & Raeford.

For more information, please visit https://www.lovepines.com/

Media Contact
Company Name: Love Pines Realty
Contact Person: Jennifer L Carlson – Owner, Broker, Realtor
Email: Send Email
Country: United States
Website: https://www.lovepines.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Stunning Fayetteville Home Hits the Market

B-Cell Non-Hodgkin Lymphoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s, “B-Cell Non-Hodgkin Lymphoma Pipeline Insight” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in B-Cell Non-Hodgkin Lymphoma pipeline landscape. It covers the B-Cell Non-Hodgkin Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the B-Cell Non-Hodgkin Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive B-Cell Non-Hodgkin Lymphoma pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive B-Cell Non-Hodgkin Lymphoma Pipeline Report to explore emerging therapies, key B-Cell Non-Hodgkin Lymphoma Companies, and future B-Cell Non-Hodgkin Lymphoma treatment landscapes @ B-Cell Non-Hodgkin Lymphoma Pipeline Outlook Report

Key Takeaways from the B-Cell Non-Hodgkin Lymphoma Pipeline Report

In February 2025:- Novartis Pharmaceuticals- This is a randomized, open label, multicenter phase III trial comparing the efficacy, safety, and tolerability of tisagenlecleucel to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline containing frontline immunochemotherapy.
In February 2025:- Regeneron Pharmaceuticals:- This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on patients with previously treated aggressive B-cell non-Hodgkin lymphoma whose cancer has stopped responding to treatment (also known as ‘refractory’) or has returned (also known as ‘relapsed’). The aim of the study is to see how safe, tolerable and effective the study drug is when given alone.
In February 2025:- Hoffmann-La Roche:- This study will assess the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin (M+P) in participants with relapsed or refractory (R/R) diffuse-large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, transformed follicular lymphoma (trFL) and FL Grade 3B (FL3B) in comparison with a commonly used regimen in this participant population, rituximab, gemcitabine and oxaliplatin (R-GemOx).
In February 2025:- Bristol-Myers Squibb:- The purpose of this study is to assess the safety, tolerability, drug levels, and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma.
DelveInsight’s B-Cell Non-Hodgkin Lymphoma pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for B-Cell Non-Hodgkin Lymphoma treatment.
The leading B-Cell Non-Hodgkin Lymphoma Companies such as Xencor, MEI Pharma, Celldex Therapeutics, TG Therapeutics, Shanghai Unicar-Therapy Bio-medicine Technology, Chia Tai Tianqing Pharmaceutical Group, Mustang Bio, Novartis, Loxo Oncology, Genmab, Nkarta, Nurix Therapeutics, Prelude Therapeutics and others.
Promising B-Cell Non-Hodgkin Lymphoma Therapies such as Bendamustine hydrochloride injection, ibrutinib, PF-3512676, Cyclophosphamide, Mitoxantrone, Vincristine, Velcade, Temsirolimus, Glofitamab, Atezolizumab, Obinutuzumab, and others.

Discover how the B-Cell Non-Hodgkin Lymphoma treatment paradigm is evolving. Access DelveInsight’s in-depth B-Cell Non-Hodgkin Lymphoma Pipeline Analysis for a closer look at promising breakthroughs @ B-Cell Non-Hodgkin Lymphoma Clinical Trials and Studies

B-Cell Non-Hodgkin Lymphoma Emerging Drugs Profile

Valemetostat: Daiichi Sankyo

Valemetostat is an investigational and potential first-in-class EZH1/2 dual inhibitor in phase II clinical development for hematologic cancers including acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), and Non-Hodgkin lymphoma (NHL), including adult T-cell leukemia/lymphoma (ATL/L), peripheral T-cell lymphoma (PTCL), and B-cell lymphomas.

MB-106: Mustang Bio

MB-106 is a CD20-targeted autologous CAR T cell therapy developed for the treatment of B-cell non-Hodgkin lymphomas (B-NHLs) and chronic lymphocytic leukemia (CLL). This therapy, optimized as a third-generation CAR derived from a fully human antibody, has shown promising results in clinical trials. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of B-cell non-Hodgkin lymphoma.

CB-010: Caribou Biosciences

CB-010, our lead clinical-stage program, is an allogeneic anti-CD19 CAR-T cell therapy designed for patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). It is the first known allogeneic CAR-T cell therapy in clinical trials to incorporate a PD-1 knockout, utilizing a genome-editing strategy aimed at enhancing antitumor activity by preventing premature CAR-T cell exhaustion. The manufacturing process for CB-010 involves three key edits using Cas9 chRDNA guides: knocking out the TRAC gene to remove the T cell receptor, site-specific insertion of an anti-CD19 CAR into the TRAC gene, and knocking out PD-1. Currently, the drug is in Phase I stage of its clinical trial for the treatment of r/r B-NHL.

LP-284: Lantern Pharma

LP-284 is an innovative small molecule drug developed by Lantern Pharma, designed to selectively target cancer cells with mutations in DNA damage repair pathways. Its development is accelerated by AI and biological modeling through Lantern’s RADR platform. The FDA has granted orphan drug designation to LP-284 for treating high-grade B-cell lymphoma (HGBL) with MYC and BCL2 rearrangements. Currently, the drug is in Phase I stage of its clinical trial.

The B-Cell Non-Hodgkin Lymphoma pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of B-Cell Non-Hodgkin Lymphoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for B-Cell Non-Hodgkin Lymphoma Treatment.
B-Cell Non-Hodgkin Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
B-Cell Non-Hodgkin Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the B-Cell Non-Hodgkin Lymphoma market.

Get a detailed analysis of the latest innovations in the B-Cell Non-Hodgkin Lymphoma pipeline. Explore DelveInsight’s expert-driven report today! @ B-Cell Non-Hodgkin Lymphoma Unmet Needs

B-Cell Non-Hodgkin Lymphoma Companies

Xencor, MEI Pharma, Celldex Therapeutics, TG Therapeutics, Shanghai Unicar-Therapy Bio-medicine Technology, Chia Tai Tianqing Pharmaceutical Group, Mustang Bio, Novartis, Loxo Oncology, Genmab, Nkarta, Nurix Therapeutics, Prelude Therapeutics and others.

B-Cell Non-Hodgkin Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

B-Cell Non-Hodgkin Lymphoma Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Download DelveInsight’s latest report to gain strategic insights into upcoming B-Cell Non-Hodgkin Lymphoma Therapies and key B-Cell Non-Hodgkin Lymphoma Developments @ B-Cell Non-Hodgkin Lymphoma Market Drivers and Barriers, and Future Perspectives

Scope of the B-Cell Non-Hodgkin Lymphoma Pipeline Report

Coverage- Global
B-Cell Non-Hodgkin Lymphoma Companies- Xencor, MEI Pharma, Celldex Therapeutics, TG Therapeutics, Shanghai Unicar-Therapy Bio-medicine Technology, Chia Tai Tianqing Pharmaceutical Group, Mustang Bio, Novartis, Loxo Oncology, Genmab, Nkarta, Nurix Therapeutics, Prelude Therapeutics and others.
Promising B-Cell Non-Hodgkin Lymphoma Therapies– Bendamustine hydrochloride injection, ibrutinib, PF-3512676, Cyclophosphamide, Mitoxantrone, Vincristine, Velcade, Temsirolimus, Glofitamab, Atezolizumab, Obinutuzumab, and others.
B-Cell Non-Hodgkin Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
B-Cell Non-Hodgkin Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in B-Cell Non-Hodgkin Lymphoma drug development? Find out in DelveInsight’s exclusive B-Cell Non-Hodgkin Lymphoma Pipeline Report—access it now! @ B-Cell Non-Hodgkin Lymphoma Emerging Drugs and Major Companies

Table of Content

Introduction
Executive Summary
B-Cell Non-Hodgkin Lymphoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
B-Cell Non-Hodgkin Lymphoma– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Drug name: Company name
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Valemetostat: Daiichi Sankyo
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
CB-010: Caribou Biosciences
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
B-Cell Non-Hodgkin Lymphoma Key Companies
B-Cell Non-Hodgkin Lymphoma Key Products
B-Cell Non-Hodgkin Lymphoma- Unmet Needs
B-Cell Non-Hodgkin Lymphoma- Market Drivers and Barriers
B-Cell Non-Hodgkin Lymphoma- Future Perspectives and Conclusion
B-Cell Non-Hodgkin Lymphoma Analyst Views
B-Cell Non-Hodgkin Lymphoma Key Companies
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/cart-cell-therapy-competitive-landscape

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: B-Cell Non-Hodgkin Lymphoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

Non-Postoperative Acute Pain Drugs Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Prevalence, Incidence, NDA Approval, Therapies, and Companies by DelveInsight

“Non-Postoperative Acute Pain Drugs Market”

Non-postoperative acute pain companies include Vertex Pharmaceuticals, H. Lundbeck A/S, Satsuma Pharmaceuticals, Axsome Therapeutics, Allodynic Therapeutics, among others.

(Albany, USA) DelveInsight’s Non-Postoperative Acute Pain Market Insights report includes a comprehensive understanding of current treatment practices, non-postoperative acute pain emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into the United States, EU4 and The UK, and Japan.

The Non-Postoperative Acute Pain market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Non-Postoperative Acute Pain market size from 2020 to 2034, segmented by seven major markets. The Non-Postoperative Acute Pain Market Report also covers current Non-Postoperative Acute Pain treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Non-Postoperative Acute Pain market.

Request for sample report @ Non-Postoperative Acute Pain Market Insights

Key Takeaways from the Non-Postoperative Acute Pain Market Report

According to DelveInsight’s analysis, the market size of Non-postoperative Acute Pain in the seven major markets was around USD 3,600 million in 2023.
DelveInsight’s analysis reveals that the overall incident population of non-postoperative acute pain in the US was reported as ~53 million in 2022.
In the United States, about 50% of the individuals diagnosed with non-postoperative acute pain experienced a moderate level of severity.
Leading non-postoperative acute pain companies such as Vertex Pharmaceuticals, H. Lundbeck A/S, Satsuma Pharmaceuticals, Axsome Therapeutics, Allodynic Therapeutics, and others are developing novel non-postoperative acute pain drugs that can be available in the non-postoperative acute pain market in the coming years.
The promising non-postoperative acute pain therapies in the pipeline include VX-548, Eptinezumab, STS101 (DHE Nasal Powder), AXS-07, Naltrexone-Acetaminophen, and others.

Discover which therapies are expected to grab the major non-postoperative acute pain market share @ Non-Postoperative Acute Pain Market Report

Non-Postoperative Acute Pain Overview

Non-postoperative acute pain pertains to immediate discomfort stemming from various origins unrelated to surgical interventions. It can arise from diverse factors such as injuries, illnesses, trauma, burns, cuts, infections, or tissue damage. The pain may manifest in different areas of the body, necessitating a systematic diagnostic strategy that encompasses patient history, physical examination, and, if deemed essential, imaging or laboratory tests. The objective is to pinpoint the origin and characteristics of the pain to devise a customized treatment plan. Managing non-surgical acute pain may involve the use of analgesic medications, implementation of physical therapy, and addressing the underlying medical condition. A holistic, multidisciplinary approach is frequently indispensable to ensure thorough care and efficient alleviation of pain for individuals undergoing non-surgical acute pain.

Non-Postoperative Acute Pain Epidemiology Segmentation

The non-postoperative acute pain epidemiology section provides insights into the historical and current non-postoperative acute pain patient pool and forecasted trends for the US. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.

The non-postoperative acute pain market report proffers epidemiological analysis for the study period 2020–2034 in the US segmented into:

Total Diagnosed Incident Cases of Non-Postoperative Acute Pain
Type-specific Cases of Non-Postoperative Acute Pain
Severity-specific Cases of Non-Postoperative Acute Pain
Total Treated Cases of Non-Postoperative Acute Pain

Non-Postoperative Acute Pain Treatment Market

Acute pain arises from various sources such as injury, surgery, illness, trauma, or painful medical procedures, acting as a signal for underlying health issues or bodily threats. Typically, it is short-lived and diminishes once the root cause is addressed or healed. Achieving optimal pain relief requires a multimodal treatment approach, which is essential in minimizing side effects by combining different methods. Key components of this approach include nerve blocks or epidurals, opioids or alternative analgesics, supplementary medications, physical modalities like RICE (rest, ice, compression, elevation), and rehabilitation. Additionally, psychosocial interventions such as distraction, meditation, and deep breathing play integral roles.

The current non-postoperative acute pain treatment strategy encompasses a variety of approaches categorized into pharmacologic and nonpharmacological therapies. In today’s non-postoperative acute pain treatment market, options like opioids, NSAIDs, and other anesthetics are available. The efficacy of pain relief is paramount, especially in the context of patients undergoing surgery. Consequently, there is anticipation within the pain market for innovative therapies that significantly contribute to alleviating pain.

To know more about non-postoperative acute pain treatment guidelines, visit @ Non-Postoperative Acute Pain Management

Non-Postoperative Acute Pain Pipeline Therapies and Key Companies

VX-548: Vertex Pharmaceuticals
Eptinezumab: H. Lundbeck A/S
STS101 (DHE Nasal Powder): Satsuma Pharmaceuticals
AXS-07: Axsome Therapeutics
Naltrexone-Acetaminophen: Allodynic Therapeutics

Learn more about the FDA-approved drugs for non-postoperative acute pain @ Drugs for Non-Postoperative Acute Pain Treatment

Non-Postoperative Acute Pain Market Dynamics

The dynamics of the non-postoperative acute pain market are expected to change in the coming years. As awareness around pain management increases, there is a growing demand for innovative solutions that extend beyond the realm of postoperative care. The non-postoperative acute pain market is witnessing a shift towards a more patient-centric approach, with an emphasis on personalized and multimodal pain management strategies. Additionally, the pharmaceutical sector is responding with the development of novel analgesics that aim to balance efficacy with reduced side effects, addressing concerns surrounding opioid use.

Furthermore, many potential therapies are being investigated for the treatment of non-postoperative acute pain, and it is safe to predict that the treatment space will significantly impact the non-postoperative acute pain market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the non-postoperative acute pain market in the 7MM.

However several factors may impede the growth of the non-postoperative acute pain market. One key obstacle is the complexity of pain itself, as it often arises from diverse sources and manifests differently among individuals. This diversity makes it challenging to create universal treatments that cater to the varying nature of non-postoperative acute pain.

Moreover, non-postoperative acute pain treatment poses a significant economic burden and disrupts patients’ overall well-being and QOL. Furthermore, the non-postoperative acute pain market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the non-postoperative acute pain market growth.

Scope of the Non-Postoperative Acute Pain Market Report

Study Period: 2020–2034
Coverage: The United States, EU5, Japan
Non-Postoperative Acute Pain Market Size in 2022: USD 3 Billion
Key Non-Postoperative Acute Pain Companies: Vertex Pharmaceuticals, H. Lundbeck A/S, Satsuma Pharmaceuticals, Axsome Therapeutics, Allodynic Therapeutics, and others
Key Pipeline Non-Postoperative Acute Pain Therapies: VX-548, Eptinezumab, STS101 (DHE Nasal Powder), AXS-07, Naltrexone-Acetaminophen, and others
Therapeutic Assessment: Non-Postoperative Acute Pain current marketed and emerging therapies
Non-Postoperative Acute Pain Market Dynamics: Key Market Forecast Assumptions of Emerging Non-Postoperative Acute Pain Drugs and Market Outlook
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Unmet Needs, KOL’s views, Analyst’s views, Non-Postoperative Acute Pain Market Access and Reimbursement

Discover more about non-postoperative acute pain drugs in development @ Non-Postoperative Acute Pain Clinical Trials

Table of contents:

1. Non-Postoperative Acute Pain Key Insights

2. Non-Postoperative Acute Pain Report Introduction

3. Non-Postoperative Acute Pain Overview at a Glance

4. Non-Postoperative Acute Pain Executive Summary

5 Non-Postoperative Acute Pain Key Events

6 Epidemiology and Market Forecast Methodology

6. Disease Background and Overview

7. Non-Postoperative Acute Pain Treatment and Management

8. Non-Postoperative Acute Pain Guidelines

9. Non-Postoperative Acute Pain Epidemiology and Patient Population

10. Patient Journey

11. Key Endpoints in Non-Postoperative Acute Pain

12. Non-Postoperative Acute Pain Marketed Drugs

13. Non-Postoperative Acute Pain Emerging Drugs

14. US Non-Postoperative Acute Pain Market Analysis

15. Market Access and Reimbursement

16. KOL Views

17. Unmet Needs

18. SWOT Analysis

19. Appendix

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/aacr-annual-meeting

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Non-Postoperative Acute Pain Drugs Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Prevalence, Incidence, NDA Approval, Therapies, and Companies by DelveInsight

LockBoard Revolutionizes Workplace Safety and Efficiency with Innovative Lockout Tagout Solution

LockBoard, a groundbreaking safety management solution, today announced its comprehensive system designed to transform workplace safety protocols and operational efficiency across industries.

The innovative LockBoard system addresses critical challenges in workplace safety management by integrating key security, documentation, and organization into a single, streamlined platform. Unlike traditional lockout tagout methods that rely on cumbersome paperwork and disorganized key storage, LockBoard provides a smart, integrated approach to protecting workers and maintaining regulatory compliance.

Key features of the LockBoard system include:

Unified Key and Documentation Storage: Combines locks, keys, and related paperwork in one easily accessible package, so you can keep track of your OSHA lockout/tagout checklist easily
Enhanced Workplace Visibility: Enables quick identification and organization of job-specific safety equipment
Flexible Mounting Options: Easily installable on walls, pegboards, and plywood displays for maximum accessibility
Comprehensive Safety Verification: Provides instant confirmation that protective keys are securely locked and maintained

The system addresses multiple workplace safety challenges:

Eliminates time-consuming searches through disorganized lock boxes
Ensures critical safety documentation is always readily available
Supports efficient auditing processes
Reduces risks associated with misplaced or untracked safety equipment

Recent industry reports highlight that workplace accidents cost businesses billions annually, with inefficient safety management being a significant contributor. LockBoards directly addresses these economic and human capital risks by providing a systematic approach to safety protocol management. The system not only protects workers but also helps companies optimize their operational workflows, potentially reducing insurance costs and improving overall workplace productivity.

LockBoards represents a smart investment for businesses seeking to optimize workplace safety and operational efficiency. By consolidating safety protocols into an intuitive, user-friendly system, companies can reduce potential hazards while streamlining administrative processes.

Businesses across manufacturing, construction, maintenance, and industrial sectors can benefit from the LockBoard system’s innovative approach to safety management.

For more information about LockBoards and how they can transform workplace safety protocols, visit https://lockboards.com.

About LockBoard:

LockBoard specializes in innovative safety solutions for industrial and commercial facilities. With a commitment to quality and reliability, LockBoard is dedicated to enhancing safety protocols across various industries, ensuring a safer work environment for all.

Media Contact
Company Name: LockBoard
Contact Person: Craig Bertucci
Email: Send Email
Country: United States
Website: https://www.lockboards.com/

Prime Sports Institute Celebrates Six Years of Innovative Athletic Performance and Recovery

Prime Sports Institute, a leading downtown Bellingham massage and athletic therapy center, is proud to mark its sixth year of delivering comprehensive sports performance and recovery services to athletes and active individuals in the Pacific Northwest.

Since its establishment in 2018, Prime has distinguished itself through an integrated approach to sports healthcare, offering a unique blend of athletic therapy, massage, and guided recovery services. The institute’s mission centers on optimizing athletic performance, preventing injuries, and enabling comprehensive recovery for clients across all fitness levels.

Comprehensive Services

Prime’s service offerings include:

Athletic Recovery: Utilizing cutting-edge recovery equipment and expert guidance to help athletes recuperate more effectively
Performance Training: Customized coaching programs designed to improve technique, build strength, and enhance overall athletic performance
Integrated Healthcare: A collaborative approach with practitioners working together to provide holistic treatment under one roof

The institute’s innovative methodology combines advanced therapeutic techniques with personalized care, setting it apart in the sports medicine landscape. By integrating athletic therapy, targeted training, and sophisticated recovery strategies, Prime enables athletes to achieve their peak potential while minimizing injury risk.

Commitment to Excellence

Prime’s team of specialized practitioners brings extensive experience and a patient-centered approach to every interaction. Their commitment to individualized care ensures that each client receives a tailored treatment plan addressing their unique physiological needs and performance goals.

Located in the heart of downtown Bellingham, the institute serves a diverse range of clients, from professional athletes to weekend warriors and fitness enthusiasts seeking to optimize their physical performance and well-being.

Community Impact and Future Vision

Prime has not only transformed individual athletic performance but has also become a cornerstone of Bellingham’s sports medicine community. By continuously investing in advanced technologies and maintaining a forward-thinking approach to athletic care, the institute has positioned itself as a leader in sports rehabilitation and performance optimization.

Looking ahead, Prime remains committed to expanding its range of services, incorporating the latest research in sports medicine, and continuing to support athletes of all levels in achieving their highest potential. The institute’s ongoing dedication to innovation and personalized care promises to drive meaningful improvements in athletic performance and recovery for years to come.

For more information about Prime Sports Institute, visit primebellingham.com or contact the institute directly.

About Prime Sports Institute:

Located in Bellingham, Prime Sports Institute is a premier sports medicine institute specializing in athletic therapy, sports massage, and guided recovery. With a team of expert practitioners and access to the latest recovery equipment, Prime is committed to helping athletes optimize their performance and achieve their full potential.

Media Contact
Company Name: Prime Sports Institute
Contact Person: Kerry Gustafson
Email: Send Email
Country: United States
Website: https://www.primebellingham.com

Oakland Vlogger Zennie Abraham: Bring NBA Team To Oakland After All-Star Week

Oakland – Tired of the outsized attention San Francisco is getting for hosting the 2025 NBA All Star Game, Oakland Vlogger and Las Vegas and NFL Vlogger Zennie Abraham, CEO of Zennie62Media, Inc (zennie62media.com) creator of The Vlog Report With Zennie62 Oakland Las Vegas NFL on YouTube, ZennieReport.com, builder of The Oakland Baseball Simworld and founder of Sports Business Simulations, Oakland’s first blogger and vlogger, once aide to two Mayors of Oakland, and the only person in history to form a bid for Oakland to host the NFL Super Bowl Game, believes that Oakland’s not taking bold steps to improve its blighted condition. To remedy this, he wants the NBA to bring a new team to Oakland to replace the Golden State Warriors.

In a recent vlog called “OAKLAND VLOGGER Zennie Abraham: NBA All-Star Game Isn’t At Oracle Arena, Oakland Needs An NBA Team”, and is here: https://www.youtube.com/watch?v=unneIlbQ_E4

Zennie said that “Oracle Arena looks like it’s ready to host the 2025 NBA All-Star Game”, and the logo on its iconic glass walls would have one believe that the game was going to be played there. Mr. Abraham thinks the City of Oakland is not aggressive in doing the one thing the 20th Century Oakland had no problem doing; going after sports teams it lost to relocation. In that case, the Oakland Raiders, which moved to Los Angeles. Zennie says Oakland has lost its “mojo” and needs to get it back.

“The best way Oakland can get its mojo back is by actually going to work on formally bringing professional sports back to Oakland”, Zennie said. “Oakland lost all of its teams during a tight window of years in this century. And the basic reason for the loss is Oakland forgot how to use tax increment financing and started leaning on general obligation bond issues far too much.

The result is an Oakland electorate that’s overextended with fees and extra property tax adjustments, making the actual rate Oakland homeowners pay just over six percent, where the 1978 original Proposition 13 tax rate was one percent. We’re not using the very tool designed to be a catalyst for new development, which in turn removes blight, and that’s tax increment financing.”

Zennie Abraham adds that the other problem is a simple lack of vision or fear to offer a vision. He uses the Port of Oakland Howard Terminal Development Project as one example. In that, the City of Oakland and the Port of Oakland did not choose the land use that should go there after they failed to reach a deal with the Oakland A’s in late 2021.

Instead, the then-new Oakland Mayor Sheng Thao used the A’s as a political football and acted unprofessionally with A’s President Dave Kaval, and Major League Baseball Commissioner Rob Manfred, and used the media to annoy A’s brass. What she failed to realize was that the A’s and Major League Baseball were serious about leaving Oakland. And by the time it became clear that was the case (and the City started forming draft documents leading to the use of tax increment financing in the proposed enhanced infrastructure financing district) the A’s were winning the right to come to Las Vegas via the Nevada Legislature.

So, what does the Port of Oakland do and the City of Oakland do? Rather than focus and form their own developer team and build the first-class million-square-feet convention center and hotel complex Oakland needs, they put the development conversation out to the public and ask for proposals for different land uses. “That invites the kind of politics that killed Howard Terminal the first time,” Zennie said. “It’s like we, and by that I mean Oakland, don’t want to learn and do better.”

Zennie says that instead of true vision we have public officials and city leaders who are afraid to ask for help from Oaklanders who have been involved, like himself. “And then you get folks running for office who say they will hire me after they get elected, rather than doing anything as a group right now. And I did not ask them for a job so I take it as an insult.” Zennie says that “politics is too important to be left to politicians, but we seem to be focused only on politicians or people who want to be one. That’s why Oakland’s ahead down the wrong road, and continues to go there.”

Zennie Abraham says “The NBA could help put Oakland on the right path just by NBA Commissioner Adam Silver calling for the City of Oakland to assemble a task force not just of politicians, but also business and community leaders and also citizens who just want to contribute their ideas, all to bring the NBA back to Oakland.”

Zennie adds that NFL Commissioner Roger Goodell could add his voice to that of Adam Silver’s and ask for the same project focused on an NFL team for Oakland. “That would help Ray Bobbitt and AASEG,” Zennie asserts, “who are the owners of the Oakland Coliseum Complex now, but without a good roadmap to move forward with.”

Something much like Oakland Sharing the Vision in 1991, where 500 Oaklanders gathered at the downtown Oakland convention center to agree on a set of goals and objectives for the future. That document helped shape Oakland over the next 15 years, but now that period of time is gone. “Its time for a new Oakland: Sharing the Vision”, Zennie says.

To view original press release, please visit: https://prgun.com/press-release/99910/oakland-vlogger-zennie-abraham-bring-nba-team-to-oakland-after-all-star-week

Media Contact
Company Name: ZENNIE62MEDIA, Inc
Contact Person: Zennie Abraham
Email: Send Email
Phone: 510-517-7565
State: Oakland
Country: United States
Website: https://zennie62media.com/

Fusion HVAC & Appliance Repair Expands Emergency HVAC Services for NYC Homeowners and Businesses

24/7 Rapid Response Team Ensures Fast, Reliable Heating and Cooling Repairs Across New York City

Manhattan, NY – Fusion HVAC & Appliance Repair, a leading provider of residential and commercial HVAC services, has announced the expansion of its emergency repair services to better serve homeowners and businesses in New York City. With round-the-clock availability, expert technicians, and a commitment to customer satisfaction, the company ensures that HVAC and essential appliance issues are resolved promptly and efficiently.

The demand for immediate heating and cooling repairs has surged as extreme temperatures become more common. Recognizing this need, Fusion HVAC & Appliance Repair has strengthened its emergency service offerings, ensuring that clients receive fast, reliable solutions 7 days a week.

“The company’s mission is to help out. Money is a byproduct of excellence, not a goal,” said Alex K., spokesperson for Fusion HVAC & Appliance Repair. “By expanding our emergency services, we’re making sure that no one is left without heating in the winter or cooling in the summer. Whether it’s a broken furnace, an air conditioning failure, or an urgent appliance repair, our expert team is ready to respond promptly.”

Fusion HVAC & Appliance Repair’s emergency services cover a wide range of HVAC systems and appliances, including:

Rooftop packaged unit emergency repair
Air conditioning units and ductless mini-split systems
Heating systems (furnaces, boilers, heat pumps)
Commercial and residential refrigeration systems
Essential kitchen and restaurant appliances

The company’s certified technicians are trained to diagnose and fix issues quickly, using state-of-the-art tools and techniques to restore functionality with minimal downtime. In addition to emergency services, Fusion HVAC & Appliance Repair provides preventive maintenance plans to help customers avoid costly breakdowns and improve energy efficiency.

With a reputation built on trust, transparency, and top-quality service, Fusion HVAC & Appliance Repair backs all repairs with up to 1-year warranty, reinforcing their commitment to long-lasting solutions.

About Fusion HVAC & Appliance Repair

Based in Manhattan, Fusion HVAC & Appliance Repair specializes in HVAC system and appliance repair for both residential and commercial clients. With a team of experienced technicians, the company provides reliable, efficient, and affordable services designed to keep homes and businesses running smoothly. From emergency repairs to routine maintenance, Fusion HVAC & Appliance Repair is dedicated to delivering exceptional customer service and high-quality workmanship.

Media Contact
Company Name: Fusion HVACR & Appliance Repair
Contact Person: Alex K.
Email: Send Email
Phone: (332) 334-4002
Address:242 Columbus Ave
City: New York
State: NY 10023
Country: United States
Website: https://fusionhvacappliance.repair

GlobalTech Horizons Asia (GTH-Asia) Expands Operations to Strengthen Regional Presence

GTH-Asia Launches Strategic Expansion to Enhance Investment and Technological Growth Across Key Asian Markets.

GlobalTech Horizons Asia (GTH-Asia), the regional arm of GlobalTech Horizons Group (GTH-Group), announces the launch of its operations across Asia, reinforcing its commitment to driving economic development, fostering strategic investments, and pioneering industry-leading innovations in financial and business sectors.

With Asia continuing to solidify its position as a global economic powerhouse, GTH-Asia is strengthening its regional presence by establishing new offices, upgrading its digital infrastructure, and forming strategic partnerships in key financial hubs. This expansion aligns with GTH-Asia’s mission to bridge international investors with Asia’s most dynamic and high-growth opportunities.

As part of this initiative, GTH-Asia has selected Singapore as its regional headquarters, positioning itself as a major force in the Asian financial landscape. The company’s first phase of expansion will focus on Singapore, Thailand, Australia and Malaysia, targeting high-impact sectors and market-driven opportunities.

“Our expansion into key Asian markets underscores our unwavering commitment to sustainable economic growth and financial inclusivity,” commented Omar Fahd Al Najjar, Group CEO of GTH-Group. “At GTH-Asia, we believe in harnessing innovation and collaboration to unlock investment potential that drives prosperity across industries. As a family-led enterprise, our goal is to create a lasting legacy of financial excellence, transparency, and responsible investment. To accelerate this vision, GTH-Group is committing $250 million USD toward emerging opportunities across Asia in the coming years.”

GTH-Asia’s expansion is marked by several key developments, including the establishment of new offices in leading financial centers, the enhancement of digital investment platforms, and collaborations with major financial institutions, regulatory bodies, and industry leaders. The company is also committed to advancing Environmental, Social, and Governance (ESG) strategies to align with sustainable investment practices.

A Vision for the Future

The expansion of GTH-Asia is a pivotal step in GTH-Group’s broader strategy to drive global financial empowerment and technological advancement. By emphasizing corporate governance, data-driven decision-making, and investor-first principles, GTH-Asia is poised to connect high-value investment opportunities with global stakeholders.

For more information about GTH-Asia and its expansion initiatives, visit www.GTH-Asia.com or explore our global initiatives at www.GTH-Group.com.

About GlobalTech Horizons Group (GTH-Group)

GlobalTech Horizons Group (GTH-Group) is a recognized leader in large-scale infrastructure and financial technology projects that have set new industry benchmarks. Since its founding in 2018, GTH-Group has evolved into a global force in financial technology, strategic investment, and market innovation. Its ability to execute large-scale projects has solidified its reputation as a trusted partner in reshaping economic ecosystems worldwide. GTH-Group oversees a global investment portfolio exceeding $3 billion USD AUM, with a strong focus on high-impact sectors.

Through a family-led governance model, GTH-Group prioritizes long-term economic value, pioneering advanced investment methodologies, and championing corporate transparency. By leveraging extensive market intelligence, robust technological frameworks, and strategic foresight, GTH-Group remains at the forefront of financial and investment innovation.

Media Contact
Company Name: GlobalTech Horizons Group (GTH-Group)
Contact Person: Info
Email: Send Email
Address:The Offices 3 – One Central, Dubai World Trade Centre, Building C3 – Level 3 & Level 5 – DWTC – Trade Centre 2
City: Dubai
Country: United Arab Emirates
Website: https://www.gth-group.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: GlobalTech Horizons Asia (GTH-Asia) Expands Operations to Strengthen Regional Presence

Diffuse Large B-Cell Lymphoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s, “Diffuse Large B-Cell Lymphoma Pipeline Insight” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Diffuse Large B-Cell Lymphoma pipeline landscape. It covers the Diffuse Large B-Cell Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diffuse Large B-Cell Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Diffuse Large B-Cell Lymphoma pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Diffuse Large B-Cell Lymphoma Pipeline Report to explore emerging therapies, key Diffuse Large B-Cell Lymphoma Companies, and future Diffuse Large B-Cell Lymphoma treatment landscapes @ Diffuse Large B-Cell Lymphoma Pipeline Outlook Report

Key Takeaways from the Diffuse Large B-Cell Lymphoma Pipeline Report

In February 2025:- Genmab:- This study will assess how safe and effective epcoritamab plus lenalidomide (E-Len) is compared to rituximab plus gemcitabine and oxaliplatin (R-GemOx) )in treating adult participants with relapsed or refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Adverse events and change in disease condition will be assessed.
In February 2025:- Pfizer:- This study is seeking participants who are unable or unwilling to undergo an autologous stem cell transplantation (when doctors put healthy blood cells back into your body) or CAR-T immune cell therapy. DLBCL is a type of non-Hodgkin lymphoma (NHL). NHL is a cancer of the lymphatic system. It develops when the body makes abnormal lymphocytes. These lymphocytes are a type of white blood cell that normally help to fight infections.
In February 2025:- Hoffmann-La Roche- The main goal of this trial is to study the frequency and severity of cytokine release syndrome (CRS) in participants with diffuse large B-cell lymphoma (DLBCL) who are using a combination of glofitamab + gemcitabine + oxaliplatin (Glofit-GemOx) followed by glofitamab-only treatment.
In February 2025:- Incyte Corporation:- This is an open-label, multicentre study too Evaluate the Safety and Pharmacokinetics of a Modified Tafasitamab IV Dosing Regimen Combined with Lenalidomide (LEN) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) who have had at least one, but no more than three prior systemic regimens and who are not eligible for high dose chemotherapy (HDC) with autologous stem-cell transplantation (ASCT) at the time of study entry.
DelveInsight’s Diffuse Large B-Cell Lymphoma pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Diffuse Large B-Cell Lymphoma treatment.
The leading Diffuse Large B-Cell Lymphoma Companies such as Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, OncoNano Medicine, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology and others.
Promising Diffuse Large B-Cell Lymphoma Therapies such as Ibrutinib, Bendamustine, Rituximab, R-miniCHOP, Selinexor, Tafasitamab, Lenalidomide, and others.

Discover how the Diffuse Large B-Cell Lymphoma treatment paradigm is evolving. Access DelveInsight’s in-depth Diffuse Large B-Cell Lymphoma Pipeline Analysis for a closer look at promising breakthroughs @ Diffuse Large B-Cell Lymphoma Clinical Trials and Studies

Diffuse Large B-Cell Lymphoma Emerging Drugs Profile

Brentuximab vedotin: Pfizer

Brentuximab vedotin (Adcetris) is an anti-neoplastic agent. It is indicated for the treatment of patients with Classical Hodgkin lymphoma (HL) after failure of autologous hematopoietic stem cell transplantation (auto-HSCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates. Adcetris is also indicated for the treatment of adult patients with CD30+ Hodgkin lymphoma at increased risk of relapse or progression following autologous stem cell transplant (ASCT), also indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma, for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) and CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy, for the treatment of adult patients with relapsed or refractory CD30+ cutaneous T- cell lymphoma (CTCL) after at least 1 prior systemic therapy. Adcetris is indicated for the first-line pediatric treatment for CD30-positive Hodgkin lymphoma. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma.

THOR-707: Sanofi

THOR-707 is a precisely PEGylated version of IL-2, where the PEG chain is attached to a novel amino acid inserted at a location on IL-2 that prevents it from engaging the alpha-receptor and binding to immune receptors that cause drug toxicities (IL-2R-alpha, CD25). The engineered IL-2 retains near-native binding to the beta-gamma receptors that selectively expand tumor-killing T effector cells and Natural Killer (NK) cells without the alpha-mediated immunosuppressive effects of regulatory T cells or eosinophil-mediated vascular leak syndrome. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma.

Abexinostat: Xynomic Pharmaceuticals

Abexinostat (Xynomic Pharmaceuticals) is a broad histone deacetylase (HDAC) inhibitor. HDAC enzymes (also known as lysine deacetylase) cleave acetyl groups from N-acetyl lysine amino acids on a histone. HDAC inhibition leads to highly acetylated histones and chromatin reshaping. In addition to altering histone acetylation, HDAC inhibitors can also influence the degree of acetylation on non-histone proteins, increasing or repressing their activity. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Diffuse Large B-cell lymphoma.

RNK05047: Ranok Therapeutics

RNK05047 is a first-in-class, small-molecule, tumor- and BRD4-selective protein degrader that was discovered and developed using Ranok’s proprietary approach to targeted protein degradation, CHAMPTM. The bromodomain transcription factor BRD4 is a key regulator of oncogenes such as MYC and BCL2 and is involved in diverse cancer types. CHAMP-1 is a Phase I/II trial of RNK05047 currently underway in the US that will assess its safety, tolerability, and pharmacokinetics, and also includes measures of anti-tumor activity and pharmacodynamics readouts as secondary endpoints.

BMF-219: Biomea Fusion

BMF-219 is an oral investigational covalent menin inhibitor. Data suggests that optimized covalent inhibitors can provide deeper inhibition while being better tolerated than some conventional reversible inhibitors. BMF-219 is being developed for genetically defined AML, ALL, DLBCL, MM and CLL patients. BMF-219 blocks the interaction of menin and MLL (AML, ALL), and limits the activity and/or expression of NPM1, MYC, HOX, and MEIS1, all known drivers of oncogenic proliferation and survival. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma.

ADI-001: Adicet Bio

ADI-001 is an investigational allogeneic gamma delta CAR T cell therapy being developed as a potential treatment for relapsed or refractory B-cell NHL. ADI-001 targets malignant B-cells via an anti-CD20 CAR and via the gamma delta innate and T cell endogenous cytotoxicity receptors. Gamma delta T cells engineered with an anti-CD20 CAR have demonstrated potent anti-tumor activity in preclinical models, leading to long-term control of tumor growth. In April 2022, ADI-001 was granted Fast Track Designation by the FDA for the potential treatment of relapsed or refractory B-cell NHL. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma.

The Diffuse Large B-Cell Lymphoma pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Diffuse Large B-Cell Lymphoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diffuse Large B-Cell Lymphoma Treatment.
Diffuse Large B-Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Diffuse Large B-Cell Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diffuse Large B-Cell Lymphoma market.

Get a detailed analysis of the latest innovations in the Diffuse Large B-Cell Lymphoma pipeline. Explore DelveInsight’s expert-driven report today! @ Diffuse Large B-Cell Lymphoma Unmet Needs

Diffuse Large B-Cell Lymphoma Companies

Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, OncoNano Medicine, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology and others.

Diffuse Large B-Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Diffuse Large B-Cell Lymphoma Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Download DelveInsight’s latest report to gain strategic insights into upcoming Diffuse Large B-Cell Lymphoma Therapies and key Diffuse Large B-Cell Lymphoma Developments @ Diffuse Large B-Cell Lymphoma Market Drivers and Barriers, and Future Perspectives

Scope of the Diffuse Large B-Cell Lymphoma Pipeline Report

Coverage- Global
Diffuse Large B-Cell Lymphoma Companies- Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, OncoNano Medicine, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology and others.
Diffuse Large B-Cell Lymphoma Therapies– Ibrutinib, Bendamustine, Rituximab, R-miniCHOP, Selinexor, Tafasitamab, Lenalidomide, and others.
Diffuse Large B-Cell Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Diffuse Large B-Cell Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Diffuse Large B-Cell Lymphoma drug development? Find out in DelveInsight’s exclusive Diffuse Large B-Cell Lymphoma Pipeline Report—access it now! @ Diffuse Large B-Cell Lymphoma Emerging Drugs and Major Companies

Table of Content

Introduction
Executive Summary
Diffuse Large B-Cell Lymphoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Diffuse Large B-Cell Lymphoma– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Brentuximab vedotin: Pfizer
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
THOR-707: Sanofi
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
ADI-001: Adicet Bio
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Diffuse Large B-Cell Lymphoma Key Companies
Diffuse Large B-Cell Lymphoma Key Products
Diffuse Large B-Cell Lymphoma- Unmet Needs
Diffuse Large B-Cell Lymphoma- Market Drivers and Barriers
Diffuse Large B-Cell Lymphoma- Future Perspectives and Conclusion
Diffuse Large B-Cell Lymphoma Analyst Views
Diffuse Large B-Cell Lymphoma Key Companies
Appendix

About Us

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
Country: United States
Website: https://www.delveinsight.com/report-store/cart-cell-therapy-competitive-landscape

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Diffuse Large B-Cell Lymphoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies